Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex, Inc. (ZYXI) is a Nevada-incorporated medical technology company that develops, manufactures, markets, and sells non-invasive medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. The ZYXI news feed on Stock Titan aggregates company-issued press releases and other coverage that reflect both its operating activities and its financial and regulatory developments.
News about Zynex often highlights its medical device portfolio and corporate events. Company announcements describe its efforts to provide devices that support pain management and rehabilitation and to advance patient monitoring technologies, including multi-parameter and laser-based pulse oximetry. Updates have included submissions of products such as the NiCO laser pulse oximeter for FDA 510(k) review and subsequent strategic decisions to seek commercialization partners through its Zynex Monitoring Solutions subsidiary.
Investors following ZYXI news will also see disclosures related to the company’s financial performance, liquidity, and capital structure. Recent press releases and SEC-related announcements have discussed revenue trends, the impact of a temporary payment suspension from Tricare, restructuring measures, and the company’s evaluation of strategic alternatives with the assistance of external financial advisors and a special committee of the board.
Regulatory and capital markets developments are another key theme in Zynex news. In December 2025, Zynex announced that it had voluntarily entered into Chapter 11 court-supervised financial restructuring and later reported that Nasdaq had determined to delist its common stock as a result of the Chapter 11 cases. These items, along with leadership changes and board appointments, appear in the news flow and provide context on governance and oversight.
By reviewing the ZYXI news page, readers can track company communications on product strategy, restructuring progress, leadership changes, and listing status. This consolidated view helps users understand how Zynex’s medical technology focus intersects with its financial and regulatory path over time.
Peabody (NYSE: BTU) announced that President and CEO Jim Grech was appointed Chair of the National Coal Council, with the appointment formalized at a White House meeting on January 15, 2026. The release highlights a 13% estimated rise in U.S. coal-fueled generation in 2025 and cites the IEA's estimate of 8.8 billion tonnes for 2025 global coal demand. The Department of Energy reestablished the NCC in June 2025 after its charter lapsed in 2021. Peabody operates multiple U.S. and Australian coal mines; its North Antelope Rochelle Mine produces 12% of U.S. coal.
Zynex (NASDAQ: ZYXI) announced it has voluntarily entered into a Chapter 11 court-supervised financial restructuring on December 16, 2025, supported by new financing from the company’s lenders. The company said operations will continue as usual with no impact to patients, customers, or employees. Management described the financing as a demonstration of lender confidence and said the restructuring positions Zynex for long-term success. The company provided a public case website for more information: https://dm.epiq11.com/Zynex.
Zynex (NASDAQ: ZYXI) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $13.4 million versus $50.0 million year‑ago. The company reported a net loss of ($42.9) million, or ($1.42) per share, and an Adjusted EBITDA loss of ($12.3) million. Management recorded a $30.7 million non-cash impairment tied to goodwill, intangibles and fixed assets. Cash and cash equivalents were $13.3 million as of September 30, 2025.
To address liquidity and strategic options, Zynex engaged Province, LLC, formed a Special Committee chaired by Paul Aronzon, entered a 30‑day grace period and did not make a $1.5 million interest payment on $60 million convertible notes due May 2026, and is discussing restructuring with note holders.
Zynex (NASDAQ: ZYXI) announced engagement of Province, LLC to evaluate strategic alternatives, including potential capital raises, recapitalization and restructuring, and formed an independent Special Committee to oversee the process.
Paul Aronzon was appointed to the board and named Chair of the Special Committee; director Bret Wise will also serve. The committee will work with management, Province and counsel to assess options. The company cautioned no transaction has been identified and there is no assurance a transaction will occur.
Zynex (NASDAQ: ZYXI) will host its Q3 2025 earnings conference call on Tuesday, November 18, 2025 at 9:00 AM ET (7:00 AM MT) to discuss results for the quarter ended September 30, 2025. A press release with financial results will be issued prior to the call. Management will host the call and provide a live webcast.
Dial-in numbers are U.S. & Canada: 800-836-8184 and International: 646-357-8785. A webcast link will be available at https://zynexmed.investorroom.com/. Callers are asked to dial in 5–10 minutes early.
Zynex (NASDAQ: ZYXI) announced on October 14, 2025 that Bret Wise has been appointed to its Board of Directors and will serve as Chair of the Audit Committee. Mr. Wise is a retired senior medical‑device executive with multi‑role experience at Dentsply (President, COO, CFO; CEO 2007–2016; Executive Chair 2016–2017), prior CFO roles at two public companies, and earlier service as an audit partner at KPMG. He has served on public boards including IMS Health and Pall and currently sits on private and clinical advisory boards. Company leadership said the appointment reinforces a renewed focus on financial oversight, integrity, and compliance.
Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices, has announced significant leadership changes with the arrival of Steven Dyson as CEO and several key executive appointments effective August 18, 2025.
The new leadership team includes Vikram Bajaj as CFO, bringing 20 years of med-tech sector experience, John T. Bibb as Chief Legal Officer with extensive legal and compliance background, Ajay Gopal as EVP of Sales with proven commercial leadership experience, and Agnes Powell as VP of Billing with 20 years in revenue cycle operations.
The executive leadership team will be completed by existing members Anna Lucsok (COO) and Donald Gregg (President of Zynex Monitoring Solutions). Chairman Thomas Sandgaard expressed confidence in the new team's ability to lead Zynex to new levels of success.
Zynex (NASDAQ: ZYXI) reported challenging Q2 2025 financial results, with net revenue declining to $22.3 million from $49.9 million year-over-year. The company posted a net loss of ($20.0 million), or ($0.66) per share, compared to net income of $1.2 million in Q2 2024.
Two significant developments marked the quarter: the appointment of Steven Dyson as new CEO, bringing 25 years of medical technology experience, and the FDA submission of their NiCO laser pulse oximeter. The company implemented efficiency improvements targeting $40 million in annualized savings, primarily effective in Q3 and Q4. Due to leadership changes, Zynex has temporarily suspended revenue and profitability guidance.
Cash and cash equivalents stood at $17.5 million, with quarterly cash collections of $26.1 million. The company's gross profit margin decreased to 68% from 80% year-over-year, affected by the Tricare payment suspension and ongoing operational restructuring.
Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its Q2 2025 earnings conference call for July 31, 2025, at 4:15 PM ET.
The company will release its financial results for the quarter ended June 30, 2025, before the call. Management will host the call followed by a Q&A session. Participants can join via phone using the U.S. & Canada dial-in (800-836-8184) or international number (646-357-8785), or through the webcast available on the company's investor relations website.
Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices, announced that Tricare, their largest insurance customer, will continue its temporary payment suspension. Despite appealing the suspension and meeting with Tricare officials in April to present data supporting the lifting of the suspension, Tricare has decided to maintain the temporary hold while conducting further review.
The company's CEO, Thomas Sandgaard, confirmed that the suspension will remain in effect until Tricare reaches its final decision. This development represents a significant challenge for Zynex, as Tricare is identified as their largest insurance customer.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
